Literature DB >> 22649101

Essential role of TAK1 in regulating mantle cell lymphoma survival.

Daniela Buglio1, Sangeetha Palakurthi, Kate Byth, Francisco Vega, Dorin Toader, Jamal Saeh, Sattva S Neelapu, Anas Younes.   

Abstract

TGF-β-activated kinase 1 (TAK1), a member of the MAPK kinase family, plays a key role in B-cell growth and development. In the present study, we examined the potential role of TAK1 as a therapeutic target for lymphoma. Here, we show that the active phosphorylated form of TAK1 is abundantly expressed in a panel of lymphoma cell lines, including mantle cell, anaplastic large cell, and Hodgkin lymphoma cell lines. Silencing TAK1 expression via the use of siRNA inhibited the activation of NF-κB and p38 and induced apoptosis in lymphoma cell lines. Moreover, submicromolar concentrations of AZ-TAK1, a novel ATP-competitive small molecule inhibitor of TAK1, dephosphorylated TAK1, p38, and IκB-α in lymphoma cell lines. These molecular events were associated with the release of cytochrome c into the cytosol, down-regulation of X-linked inhibitor of apoptosis, activation of caspase 9, and induction of apoptosis. We also demonstrate that primary lymphoma cells express TAK1 and pTAK1 and were sensitive to AZ-TAK1-mediated cell death. Collectively, our data demonstrate an essential role for TAK1 in regulating critical survival mechanisms in lymphoma and suggest that it may serve as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22649101      PMCID: PMC3460632          DOI: 10.1182/blood-2011-07-369397

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Characterization of 4 mantle cell lymphoma cell lines.

Authors:  Hesham M Amin; Timothy J McDonnell; L Jeffrey Medeiros; Georgios Z Rassidakis; Vasiliki Leventaki; Sean L O'Connor; Michael J Keating; Raymond Lai
Journal:  Arch Pathol Lab Med       Date:  2003-04       Impact factor: 5.534

2.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

3.  Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis.

Authors:  R Morgan; S D Smith; B K Hecht; V Christy; J D Mellentin; R Warnke; M L Cleary
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

4.  TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop.

Authors:  K Kishimoto; K Matsumoto; J Ninomiya-Tsuji
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

5.  MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival.

Authors:  Bei Zheng; Paolo Fiumara; Yang V Li; Georgios Georgakis; Virginia Snell; Mamoun Younes; Jean Nicolas Vauthey; Antonino Carbone; Anas Younes
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

6.  In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells.

Authors:  Gabriel Courties; Virginia Seiffart; Jessy Presumey; Virginie Escriou; Daniel Scherman; Jochen Zwerina; Gisela Ruiz; Natalia Zietara; Jadwiga Jablonska; Siegfried Weiss; Andrea Hoffmann; Christian Jorgensen; Florence Apparailly; Gerhard Gross
Journal:  Blood       Date:  2010-08-03       Impact factor: 22.113

7.  Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma.

Authors:  A Goy; F Gilles; Y Remache; D Filippa; C S Portlock; S C Jhanwar; A D Zelenetz
Journal:  Leuk Lymphoma       Date:  2001-01

8.  Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin.

Authors:  Yoshinobu Matsuo; Hans G Drexler; Akira Harashima; Ayumi Okochi; Atsuhiko Hasegawa; Kensuke Kojima; Kunzo Orita
Journal:  Leuk Res       Date:  2004-08       Impact factor: 3.156

9.  Molecular cytogenetic aberrations in CD30+ anaplastic large cell lymphoma cell lines.

Authors:  Jean Gogusev; Louise Telvi; Christian Nezelof
Journal:  Cancer Genet Cytogenet       Date:  2002-10-15

10.  XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells.

Authors:  Hamid Kashkar; Christiane Haefs; Hwain Shin; Stephen J Hamilton-Dutoit; Guy S Salvesen; Martin Kronke; Juliane M Jurgensmeier
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

View more
  25 in total

1.  MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro.

Authors:  Feng-Ting Huang; Juan-Fei Peng; Wen-Jie Cheng; Yan-Yan Zhuang; Ling-Yun Wang; Chu-Qiang Li; Jian Tang; Wen-Ying Chen; Yuan-Hua Li; Shi-Neng Zhang
Journal:  Dig Dis Sci       Date:  2017-02-13       Impact factor: 3.199

2.  Structure-guided development of covalent TAK1 inhibitors.

Authors:  Li Tan; Deepak Gurbani; Ellen L Weisberg; John C Hunter; Lianbo Li; Douglas S Jones; Scott B Ficarro; Samar Mowafy; Chun-Pong Tam; Suman Rao; Guangyan Du; James D Griffin; Peter K Sorger; Jarrod A Marto; Kenneth D Westover; Nathanael S Gray
Journal:  Bioorg Med Chem       Date:  2016-12-09       Impact factor: 3.641

Review 3.  TAK1 regulates hepatic cell survival and carcinogenesis.

Authors:  Yoon Seok Roh; Jingyi Song; Ekihiro Seki
Journal:  J Gastroenterol       Date:  2014-01-21       Impact factor: 7.527

4.  Transforming growth factor-β-activated kinase 1 resistance limits glucocorticoid responsiveness to Toll-like receptor 4-mediated inflammation.

Authors:  Fansheng Kong; Gloria Laryea; Zhiwei Liu; Sandip Bhattacharyya
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

5.  Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

Authors:  Li Tan; Deepak Gurbani; Ellen L Weisberg; Douglas S Jones; Suman Rao; William D Singer; Faviola M Bernard; Samar Mowafy; Annie Jenney; Guangyan Du; Atsushi Nonami; James D Griffin; Douglas A Lauffenburger; Kenneth D Westover; Peter K Sorger; Nathanael S Gray
Journal:  Bioorg Med Chem       Date:  2016-12-07       Impact factor: 3.641

6.  Adenovirus-Mediated Small Interfering RNA Targeting TAK1 Ameliorates Joint Inflammation with Collagen-Induced Arthritis in Mice.

Authors:  Xinjing Luo; Yongfeng Chen; Guoju Lv; Zhidong Zhou; Jie Chen; Xuanrong Mo; Jiangwen Xie
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

7.  MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.

Authors:  Kelsey L McNew; William J Whipple; Anita K Mehta; Trevor J Grant; Leah Ray; Connor Kenny; Anurag Singh
Journal:  Mol Cancer Res       Date:  2016-09-21       Impact factor: 5.852

8.  Heterozygous Mutations in MAP3K7, Encoding TGF-β-Activated Kinase 1, Cause Cardiospondylocarpofacial Syndrome.

Authors:  Carine Le Goff; Curtis Rogers; Wilfried Le Goff; Graziella Pinto; Damien Bonnet; Maya Chrabieh; Olivier Alibeu; Patrick Nistchke; Arnold Munnich; Capucine Picard; Valérie Cormier-Daire
Journal:  Am J Hum Genet       Date:  2016-07-14       Impact factor: 11.025

9.  Side chain-functionalized aniline-derived ursolic acid derivatives as multidrug resistance reversers that block the nuclear factor-kappa B (NF-κB) pathway and cell proliferation.

Authors:  Ri-Zhen Huang; Shi-Xian Hua; Zhi-Xin Liao; Xiao-Chao Huang; Heng-Shan Wang
Journal:  Medchemcomm       Date:  2017-05-12       Impact factor: 3.597

10.  Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors.

Authors:  Johan J N Veerman; Yorik B Bruseker; Eddy Damen; Erik H Heijne; Wendy van Bruggen; Koen F W Hekking; Rob Winkel; Christopher D Hupp; Anthony D Keefe; Julie Liu; Heather A Thomson; Ying Zhang; John W Cuozzo; Andrew J McRiner; Mark J Mulvihill; Peter van Rijnsbergen; Birgit Zech; Louis M Renzetti; Lee Babiss; Gerhard Müller
Journal:  ACS Med Chem Lett       Date:  2021-03-03       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.